YOLFTbeta
06

DAE HWA Pharmaceutical Co. Ltd

067080 · KQ · Healthcare / Drug Manufacturers - Specialty & Generic

9,490.00KRW+30.00 (+0.32%)

Price History

Full chart

Market Stats

Previous Close9,460.00
Open9,550.00
Day Range9,470.00 – 9,750.00
52-Week Range7,460.00 – 24,613.93
Volume41.40K
Market Cap212.78B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield1.29%
Beta-0.13
50-Day Avg10,484.60
200-Day Avg13,110.40

About

DAE HWA Pharmaceutical Co., Ltd., a pharmaceutical company, produces and supplies pharmaceutical products in South Korea. The company offers drugs for anticancer, antibiotics, antifungal and skin ailment, antivirus, anti-allergosis, hemorrhoids, antidepressant, antiepileptic, psychotropic agent, anti respiratory, anti-inflammatory, analgesic, skeletal muscle relaxants, osteoporosis, anti-arthritis, gastro-intestinal, obesity, antispasmodic, diabetics, hypertension, hyperlipemia, antithrombotic and anticoagulant, hepatic, erectile dysfunction, urinary incontinence, prostatic hyperplasia, pregnancy, bug bite, anthelmintics, and cosmetic care, as well as vitamins and minerals, tonics, nutrition products. It also provides transdermal drug delivery system, a pharmaceutical preparation that is applied to the intact skin for systemic absorption; and active pharmaceutical ingredients. The company also exports its products to approximately 22 countries, including Asia, South America, the Middle East, and Africa. DAE HWA Pharmaceutical Co., Ltd. was founded in 1984 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOKim Eun-Seok
  • Employees0
  • Headquarters2145, Nambusunhwan-ro, Seoul, South Korea, Korea
  • Websitehttps://www.dhpharm.co.kr

Leadership

  • Mr. Byung-Tae NoChairman & President · b. 1961
  • Kim Eun-SeokCEO & Director · b. 1975
  • Hye Youn KimDirector of Development Department
  • Byung-Yoon HwangHead of Special Sales Division, Head Daegu Division and Senior Managing Director · b. 1955
  • Jae-Kwon YangHead of Choongang Research Center and Director · b. 1963
  • Young-Taek ParkHead of Hyangnam Research Center and Director · b. 1958
  • Boon-Yeon AhnHead of Information System and Director · b. 1965

Financials

Income Statement

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue142.04B143.17B128.00B134.93B139.08B142.29B122.20B110.14B114.61B109.35B117.16B131.91B141.36B149.41B143.06B
Growth (%)-+0.80%-10.60%+5.42%+3.08%+2.31%-14.12%-9.87%+4.06%-4.59%+7.15%+12.59%+7.16%+5.69%-4.25%
Cost of Revenue103.07B104.10B92.46B92.56B96.79B97.73B75.88B64.31B65.98B66.58B73.49B85.81B95.95B96.17B95.23B
Gross Profit---39.16B42.29B44.56B46.32B45.83B48.63B42.77B43.67B46.10B45.41B53.24B47.83B
Gross Margin---29.02%30.41%31.32%37.91%41.61%42.43%39.11%37.28%34.95%32.12%35.64%33.43%
Operating Expense---34.71B36.70B39.02B29.89B40.81B43.53B39.95B42.48B43.29B43.74B47.02B44.66B
Operating Income8.78B8.10B4.56B4.45B5.59B5.54B16.43B5.03B5.10B2.82B1.19B2.81B1.66B6.22B3.16B
Operating Margin6.18%5.65%3.56%3.30%4.02%3.89%13.44%4.56%4.45%2.58%1.02%2.13%1.18%4.16%2.21%
EBITDA-----------9.33B10.09B13.38B15.84B
EBITDA Margin-----------7.07%7.14%8.95%11.07%
Net Income3.76B3.15B1.68B-102.03M3.91B3.73B12.65B6.65B10.54B-2.01B2.22B1.12B-1.15B531.42M1.65B
Net Income Margin2.65%2.20%1.31%-0.08%2.81%2.62%10.36%6.04%9.20%-1.84%1.89%0.85%-0.81%0.36%1.16%
R&D972.92M-3.77B5.40B3.81B5.20B6.18B4.69B3.97B5.62B6.64B5.37B5.98B7.24B5.19B
R&D as % of Total Revenue0.68%-2.94%4.00%2.74%3.66%5.06%4.26%3.47%5.14%5.67%4.07%4.23%4.85%3.62%
Interest Expense000000004.94B5.41B1.52B2.37B4.67B5.46B4.79B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%4.31%4.94%1.30%1.79%3.31%3.65%3.35%

Balance Sheet

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets135.58B130.19B121.87B124.07B124.61B153.80B165.47B162.06B166.15B175.05B177.38B199.06B219.16B205.88B210.86B
Total Liabilities78.60B68.80B59.84B65.57B63.55B87.65B88.72B85.17B86.80B93.07B97.70B121.06B145.93B133.89B131.72B
Total Equity56.15B60.14B60.39B58.00B61.06B66.15B76.75B76.88B79.35B81.98B79.67B77.99B73.23B72.00B74.07B
Cash3.44B1.81B3.61B4.05B2.75B11.75B8.19B6.20B2.66B52.12M40.23M37.33M41.58M25.58M1.36B
Total Debt----33.61B49.58B49.24B44.96B35.25B48.76B-----
Net Debt---------59.55B65.64B86.49B105.80B97.35B95.16B

Cash Flow

Currency: KRW2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow3.43B5.77B13.57B6.18B2.43B8.79B10.94B10.49B-41.07M2.90B10.45B8.05B-590.27M6.13B5.43B
Investing Cash Flow----5.16B-3.73B-25.58B-14.98B-7.25B-3.57B-11.81B-13.50B-25.25B-15.23B5.27B-
Financing Cash Flow9.55B---583.19M107.40M25.75B510.75M-5.35B-89.92M9.62B3.65B16.32B17.05B-14.09B-
Capital Expenditure9.31B1.36B1.18B2.88B4.62B4.03B7.26B4.81B12.49B10.38B14.40B31.94B10.98B6.14B4.73B
Free Cash Flow----------7.73B-4.01B-23.74B-11.15B-894.77M699.93M
Dividends Paid1.65B1.37B1.75B1.76B1.77B1.77B1.77B2.65B2.65B2.57B2.62B2.63B2.63B2.63B2.63B
FCF to OCF----------266.51%-38.38%-295.10%1889.36%-14.61%12.90%
Dividend Paid to FCF----------33.28%-65.41%-11.07%-23.56%-293.65%375.40%

Earnings

Report DateMar 31, 2009Jun 30, 2009Sep 30, 2009Dec 31, 2009Mar 31, 2010Jun 30, 2010Sep 30, 2010Dec 31, 2010Mar 31, 2011Jun 30, 2011Sep 30, 2011Dec 31, 2011Mar 31, 2012Jun 30, 2012Sep 30, 2012Dec 31, 2012Mar 31, 2013Jun 30, 2013Sep 30, 2013Mar 31, 2014Jun 30, 2014Sep 30, 2014Dec 31, 2014Mar 31, 2015Jun 30, 2015Sep 30, 2015Dec 31, 2015Mar 31, 2016Jun 30, 2016Sep 30, 2016Dec 31, 2016Mar 31, 2017Jun 30, 2017Sep 30, 2017Dec 31, 2017Mar 31, 2018Jun 30, 2018Sep 30, 2018Dec 31, 2018Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Mar 17, 2021May 17, 2021Aug 13, 2021Nov 15, 2021Feb 23, 2022May 16, 2022Aug 11, 2022Nov 14, 2022Feb 22, 2023May 15, 2023Aug 11, 2023Nov 14, 2023Mar 28, 2024May 16, 2024Aug 9, 2024Nov 12, 2024Mar 11, 2025May 15, 2025Aug 7, 2025Nov 12, 2025Mar 12, 2026May 13, 2026Jun 30, 2026
EPS Estimate---------------------------------------------------------------------
EPS Actual78.0932.8058.30118.9787.26123.0030.33-42.8274.3242.299.1978.0933.1229.2428.3843.4038.2544.0013.2848.18-4.765.98-55.1151.3646.0820.05104.0076.2330.77-4.41108.6368.7435.2571.11589.00143.39-2.8893.46141.9936.51222.57111.01233.9950.65-60.08-47.27-59.0481.46101.2576.41-293.73103.33-56.88147.58-130.3478.65-8.51-103.10-32.51-93.4523.9610.5089.32-23.64-38.95-24.47181.38-13.69106.05
Surprise---------------------------------------------------------------------
Timing--------------------------------------------------Pre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap212.78B
Enterprise Value305.34B
Trailing P/E0.00
Forward P/E0.00
Price / Sales1.43
Price / Book2.62
Revenue (TTM)148.75B
Gross Profit (TTM)51.48B
EBITDA11.75B
Profit Margin2.98%
Operating Margin8.06%
Return on Equity6.12%
Return on Assets1.64%
Shares Outstanding18.42M
Shares Float13.72M
Beta-0.13
Dividend Yield1.29%
Dividend Rate150.00
Payout Ratio60.17%

Dividends

20261×
50.00Jun 29, 2026
20252×
100.00Dec 29, 202550.00Jun 27, 2025
20242×
100.00Dec 27, 202450.00Jun 27, 2024
20232×
100.00Dec 27, 202350.00Jun 29, 2023
20222×
100.00Dec 28, 202250.00Jun 29, 2022
20212×
100.00Dec 29, 202150.00Jun 29, 2021
20202×
100.00Dec 29, 202050.00Jun 29, 2020
20192×
100.00Dec 27, 201950.00Jun 27, 2019
20182×
100.00Dec 27, 201850.00Jun 28, 2018
20172×
100.00Dec 27, 201750.00Jun 29, 2017
20162×
50.00Dec 28, 201650.00Jun 29, 2016
20152×
50.00Dec 29, 201550.00Jun 29, 2015
20141×
50.00Dec 29, 2014